IP Library › Granted Patent US 11,319,298

Granted Patent B2

US 11,319,298 · App. 16/471,679 · Granted May 3, 2022

Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor

Inventors: Jianming Bao (San Mateo, CA); Ronald Ferguson (Scotch Plains, NJ); Xiaolei Gao (Bridgewater, NJ); Scott Harrison (Elkins Park, PA); Sandra L. Knowles (Princeton, NJ); Michael Man-Chu Lo (Bedminster, NJ); Robert D. Mazzola, Jr. (Stewartsville, NJ); Jeffrey W. Shubert (North Wales, PA)

Assignees: Merck Sharp & Dohme Corp.; MSD R&D (China) Co., Ltd.

C07D401/04 C07D401/14 C07D405/14 C07D413/14 C07D417/14 C07D491/107 C07D498/08 C07D513/04

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 11,319,298
App. No.: 16/471,679
Granted: May 3, 2022
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention is directed to heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Claims (314)

1. A compound of the formula I:

or a pharmaceutically acceptable salt thereof;

wherein:

the group:

is selected from the group consisting of:

R 1 is selected from the group consisting of: benzodioxolyl, benzoimidazolyl, benzoxazoly, benzooxazinone, benzooxazolone, benzothiazolyl, chromanyl, cyclopentapyridinyl, dihydrobenzo[1,4]dioxinyl, dihydrobenzofuranyl, dihydrobenzo[1,4]oxazinyl, dihydrofuropyridinyl, dihydroisobenzofuranyl, dihydroisoquinolinone, dihydropyranopyridinyl, dihydroimidazopyridine, dihydropyrido[1,4]oxazinyl, dihydroquinolinone, indazolyl, indanyl, indolyl, isochromanone, isobenzofuranone, isochromanyl, isoindolinyl, isoxazolyl, oxoisoindolinyl, phenyl, pyrazolopyridinyl, pyrazolyl, pyridyl, pyrrolopyridinyl, pyrimidinyl, quinolinone, quinolinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, and tetrahydropyranyl, which is substituted with one or more R 1a , R 1b and R 1c , wherein R 1a , R 1b and R 1c are independently selected from the group consisting of:

(a) hydrogen,

(b) halogen,

(c) C 1-6 alkyl, which is unsubstituted or substituted with substituents selected from the group consisting of: hydroxyl, fluoro and —NH 2 ,

(d) —O—C 1-6 alkyl, which is unsubstituted or substituted with substituents selected from the group consisting of: fluoro and —NH 2 ,

(e) C 3-6 cycloalkyl,

(f) —SO 2 —C 1-6 alkyl, and

(g) —CN;

R 2 and R 3 are independently selected from the group consisting of:

(1) hydrogen, and

(2) fluoro;

R 7 is selected from the group consisting of:

(1) halogen,

(2) C 1-6 alkyl, which is unsubstituted or substituted with hydroxy, methoxy, fluoro or —(C═O)O—C 1-6 alkyl,

(3) —CN, and

(4) —(C═O)O—C 1-6 alkyl;

R 8 is selected from the group consisting of:

(1) methyl,

(2) ethyl,

(3) -fluoro, and

(4) -chloro;

each of R 10 and R 11 is independently selected from the group consisting of:

(1) hydrogen,

(2) halogen,

(3) hydroxy,

(4) —C 1-6 alkyl, which is unsubstituted or substituted with substituents selected from the group consisting of: hydroxy, methoxy, or fluoro,

(5) —C 2-4 alkenyl,

(6) —O—C 1-6 alkyl, which is unsubstituted or substituted with substituents selected from the group consisting of: methoxy or fluoro,

(7) —C 3-6 cycloalkyl, which is unsubstituted or substituted with fluoro,

(8) —(C═O)O—C 1-6 alkyl,

(9) —(C═O)NH 2 ,

(10) —(C═O)—NH—C 3-6 cycloalkyl, which is unsubstituted or substituted with phenyl, pyridinyl, fluoro, chloro, —C 1-6 alkyl or —O—C 1-6 alkyl,

(11) —(C═O)—NH—C 1-6 alkyl, which is unsubstituted or substituted with benzodioxolyl, benzofuranyl, bicyclopentyl, imidazolyl, imidazolopyridinyl, indenyl, isothiazolyl, oxoisoindolinyl, oxopyrrolidinyl, phenyl, pyrrolidinonyl, pyrazolyl, pyridyl, pyridinyl, pyridazinyl, pyrimidinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, thiadiazolyl, thiazolyl, triazolyl, which is unsubstituted or substituted with fluoro, chloro, —C 1-6 alkyl, —CF 3 , —CN, —(SO 2 )—C 1-6 alkyl, —O—C 1-6 alkyl, phenyl, or pyridyl;

(12) —(C═O)—NH-heteroaryl or —(C═O)—NH-heterocyclyl, wherein the heteroaryl or heterocyclyl is selected from the group consisting of benzodioxolyl, benzofuranyl, bicyclopentyl, imidazolyl, imidazolopyridinyl, indenyl, isothiazolyl, oxoisoindolinyl, oxopyrrolidinyl, pyrrolidinonyl, pyrazolyl, pyridyl, pyridinyl, pyridazinyl, pyrimidinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, thiadiazolyl, thiazolyl, triazolyl, which is unsubstituted or substituted with fluoro, chloro, —C 1-6 alkyl, —CF 3 , —CN, —(SO 2 )—C 1-6 alkyl, —O—C 1-6 alkyl, phenyl, or pyridyl;

(13) —(C═O)—NH—O—C 1-6 alkyl,

(14) —(C═O)—NH—NH—C 1-6 alkyl,

(15) pyridyl,

(16) oxadiazolyl,

(17) —NH 2 ,

(18) —NH—C 1-6 alkyl or —N(C 1-6 alkyl) 2 ,which is unsubstituted or substituted with fluoro, hydroxyl, phenyl, or pyridyl,

(19) —CN,

(20) —S—C 1-6 alkyl, and

(21) —(SO 2 )—C 1-6 alkyl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is phenyl, which is unsubstituted or substituted with —CN.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is pyridyl, which is unsubstituted or substituted with —OCH 3 .

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen and R 3 is hydrogen.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is selected from the group consisting of:

(1) methyl,

(2) ethyl,

(3) —CHF 2 ,

(4) -fluoro,

(5) -chloro,

(6) -bromo,

(7) —CN,

(8) —(C═O)O-methyl, and

(9) —CH 2 (C═O)O-methyl.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each of R 10 and R 11 is independently selected from the group consisting of:

(1) hydrogen,

(2) fluoro,

(3) chloro,

(4) hydroxy,

(5) —CH 3 ,

(6) —CF 3 ,

(7) —CH 2 OH,

(8) —CH 2 CH 2 OH,

(9) —C(CH 3 ) 2 OH,

(10) —S—CH 3 ,

(11) —CH 2 OCH 3 ,

(12) cyclopropyl,

(13) —(C═O)O—CH 3 ,

(14) —(C═O)O—CH 2 CH 3 ,

(15) —(C═O)—NH-tetrahydroquinolinyl,

(16) —(C═O)—NH—CH 2 -pyridyl, and

(17) —(C═O)—NH—CH 2 -tetrahydroquinolinyl.

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each of R 10 and R 11 is independently selected from the group consisting of:

(1) hydrogen, and

(2) —C 1-6 alkyl, which is unsubstituted or substituted with hydroxy, methoxy, 1-3 fluoro.

8. A compound which is selected from the group consisting of:

4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-2,5-dimethylpyrimidine;

(4-chloro-6-(4-(3-chloro-4-methylphenoxy)piperidin-1-yl)-5-methylpyrimidin-2-yl)methanol;

3-(4-(3-cyanophenoxy)piperidin-1-yl)-5,6-dimethylpyridazine-4-carbonitrile;

4-chloro-2,5-dimethyl-6-(4-(pyridin-3-yloxy)piperidin-1-yl)pyrimidine;

4-chloro-6-((cis)-3-fluoro-4-(4-methoxyphenoxy)piperidin-1-yl)-5-methylpyrimidine;

4-chloro-5-methyl-6-(4-(pyridin-3-yloxy)piperidin-1-yl)pyrimidine;

4-chloro-5-methyl-2-(methylthio)-6-(4-(pyridin-3-yloxy)piperidin-1-yl)pyrimidine;

4-chloro-6-(4-(4-methoxyphenoxy)piperidin-1-yl)-5-methyl-2-(methylthio)pyrimidine;

methyl 2-(4-chloro-6-(4-(4-methoxyphenoxy)piperidin-1-yl)pyrimidin-5-yl)acetate;

3-((1-(6-chloro-2-(hydroxymethyl)-5-methylpyrimidin-4-yl)-3,3-difluoropiperidin-4-yl)oxy)benzonitrile;

(4-chloro-6-(4-(4-methoxyphenoxy)piperidin-1-yl)-5-methylpyrimidin-2-yl)methanol;

5-((1-(6-chloro-2-(hydroxymethyl)-5-methylpyrimidin-4-yl)piperidin-4-yl)oxy)-2-methoxybenzonitrile;

4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidine;

3-((1-(6-chloro-5-methylpyrimidin-4-yl)piperidin-4-yl)oxy)benzonitrile;

3-((1-(6-chloro-2-(hydroxymethyl)-5-methylpyrimidin-4-yl)piperidin-4-yl)oxy)benzonitrile;

(4-chloro-6-(4-((5-fluoro-6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidin-2-yl)methanol;

3-((1-(6-chloro-2,5-dimethylpyrimidin-4-yl)piperidin-4-yl)oxy)benzonitrile;

4-chloro-6-(4-(4-methoxyphenoxy)piperidin-1-yl)-5-methylpyrimidine;

4-chloro-2-(methoxymethyl)-6-(4-(4-methoxyphenoxy)piperidin-1-yl)-5-methylpyrimidine;

4-chloro-6-(4-(4-methoxyphenoxy)piperidin-1-yl)-2,5-dimethylpyrimidine;

(4-chloro-6-(4-((5-chloro-6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidin-2-yl)methanol;

(4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidin-2-yl)methanol;

4-chloro-6-(4-(4-methoxyphenoxy)piperidin-1-yl)-5-methyl-2-(methyl sulfonyl)pyrimidine;

2,4-dichloro-6-(4-(4-methoxyphenoxy)piperidin-1-yl)-5-methylpyrimidine;

4-chloro-2-(methoxymethyl)-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidine;

4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methyl-2-(methylthio)pyrimidine;

3-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5,6-dimethylpyridazine-4-carbonitrile;

6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-2,5-dimethylpyrimidin-4-amine;

6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidin-4-amine;

4-chloro-2-cyclopropyl-5-methyl-6-(4-(pyridin-3-yloxy)piperidin-1-yl)pyrimidine;

4-chloro-2-cyclopropyl-6-(4-(4-methoxyphenoxy)piperidin-1-yl)-5-methylpyrimidine;

3-((1-(2,5,6-Trimethylpyrimidin-4-yl)piperidin-4-yl)oxy)benzonitrile;

4-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-2,5,6-trimethylpyrimidine;

4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidine-2-carboxamide;

4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methyl-N-(pyridin-4-ylmethyl)pyrimidine-2-carboxamide;

4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methyl-N-(2-(pyridin-4-yl)ethyl)pyrimidine-2-carboxamide;

4-chloro-N’-isopropyl-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidine-2-carbohydrazide;

N-(bicyclo[1.1.1]pentan-1-yl)-4-chloro-6-(4-(6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidine-2-carboxamide;

4-chloro-N-((3-chloropyridin-4-yl)methyl)-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidine-2-carboxamide;

N-(tert-butyl)-4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidine-2-carboxamide;

4-chloro-N-isopropyl-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidine-2-carboxamide;

4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methyl-N-(5,6,7,8-tetrahydroisoquinolin-5-yl)pyrimidine-2-carboxamide;

N-(azetidin-3-yl)-4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidine-2-carb oxamide;

4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methyl-N-(5,6,7,8-tetrahydroisoquinolin-7-yl)pyrimidine-2-carboxamide;

4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methyl-N-(5,6,7,8-tetrahydroquinolin-7-yl)pyrimidine-2-carboxamide;

4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methyl-N-(5,6,7,8-tetrahydroquinolin-6-yl)pyrimidine-2-carboxamide;

4-chloro-N-(2-chlorobenzyl)-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidine-2-carb oxamide;

4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methyl-N-(2-(pyridin-4-yl)propan-2-yl)pyrimidine-2-carboxamide;

4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methyl-N-(1,2,3,4-tetrahydronaphthalen-2-yl)pyrimidine-2-carboxamide;

4-chloro-6-((3 S,4R)-3-fluoro-4-((6-methoxypyri din-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidine-2-carb oxamide;

(R)-4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrimidine-2-carboxamide;

(S)-4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrimidine-2-carboxamide;

4-chloro-N-(isothiazol-4-ylmethyl)-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidine-2-carboxamide;

4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methyl-2-(methylsulfonyl)pyrimidine;

4-chloro-2-methoxy-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidine;

2-((4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidin-2-yl)amino)ethan-1-ol;

4-chloro-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidin-2-ol;

(4-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5,6-dimethylpyrimidin-2-yl)methanol;

4-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5,6-dimethylpyrimidine;

3-((1-(6-ethyl-5-methylpyrimidin-4-yl)piperidin-4-yl)oxy)benzonitrile; and

4-ethyl-6-(4-((6-methoxypyridin-3-yl)oxy)piperidin-1-yl)-5-methylpyrimidine;

or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition which comprises an inert carrier and a compound of claim 1 or a pharmaceutically acceptable salt thereof.

10. A method for the treatment of a neurological and/or psychiatric disorder associated with muscarinic acetylcholine receptor dysfunction in a mammal comprising the step of administering at least one compound of claim 1 , or a pharmaceutically acceptable salt of said compound, to a patient in need thereof in an amount effective to treat said disorder.

11. The method of claim 10 , wherein the mammal has been diagnosed with a need for treatment of the disorder prior to the administering step.

12. The method of claim 10 , wherein the disorder is a neurological and/or psychiatric disorder associated with mAChR M4 dysfunction.

13. The method of claim 10 , wherein the disorder is a psychotic disorder.

14. The method of claim 13 , wherein the psychotic disorder is selected from schizophrenia, brief psychotic disorder, schizophreniform disorder, schizoaffective disorder, delusional disorder, shared psychotic disorder, catastrophic schizophrenia, postpartum psychosis, psychotic depression, psychotic break, tardive psychosis, myxedematous psychosis, occupational psychosis, menstrual psychosis, secondary psychotic disorder, bipolar I disorder with psychotic features, and substance-induced psychotic disorder.

15. The compound of claim 1 , wherein R 1 is selected from the group consisting of phenyl and pyridyl, which is substituted with one or more R 1a , R 1b and R 1c .

16. The compound of claim 15 , which is selected from the group consisting of: